Management Strategies for Immune Deficiency
(X-MAIDReg Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to better understand and treat a rare immune disorder caused by a mutation in the MOESIN gene, located on the X chromosome. People with this condition often experience frequent infections in their lungs, stomach, or urinary system. Researchers aim to develop guidelines to help doctors determine the best treatment options for each patient. Men with this specific gene mutation who agree to share their health information may be suitable candidates for the trial.
As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of people, offering participants a chance to contribute to significant advancements in treatment.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It seems that management varies widely, so it's best to discuss your specific situation with the trial coordinators.
Why are researchers excited about this trial?
X-linked Moesin Associated Immunodeficiency is a rare condition where the body's immune system doesn't work properly, often leading to severe infections. Researchers are excited about this treatment because it targets the underlying genetic cause of the disease in a way that existing treatments don't. Unlike traditional therapies that mainly focus on managing symptoms, this new treatment aims to correct the genetic defect itself, potentially providing a more lasting solution. This could mean fewer infections and a better quality of life for patients.
Who Is on the Research Team?
Isabelle ANDRE, doctor
Principal Investigator
Institut National de la Santé Et de la Recherche Médicale, France
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive various treatments including immunoglobulin substitution, antibiotic prophylaxis, and potentially hematopoietic stem cell transplantation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Hematopoietic Stem Cell Transplantation
- Immunoglobulin Substitution
- Prophylactic Antibiotics
Find a Clinic Near You
Who Is Running the Clinical Trial?
Institut National de la Santé Et de la Recherche Médicale, France
Lead Sponsor